ELISA for the core protein of the cartilage large aggregating proteoglycan, aggrecan: Comparison with the concentrations of immunogenic keratan sulphate in synovial fluid, serum and urine

doi:10.1016/0009-8981(94)90026-4

Clinica Chimica Acta

Volume 225, Issue 1, February 1994, Pages 43-55

https://doi.org/10.1016/0009-8981(94)90026-4 Get rights and content

Abstract

Immunological assays for fragments of the cartilage large aggregating proteoglycan, aggrecan, have been widely used to monitor cartilage turnover. These assays have commonly employed the monoclonal keratan sulphate antibody, 5D4. Keratan sulphate, however, is present in many tissues and 5D4 affinity is critically dependent on antigen structure. We have therefore raised and characterized a monoclonal antibody (1-F21) that reacts with the core protein of aggrecan without interference from the glycosaminoglycan side chains and, using this antibody, we have optimized a sensitive, competitive ELISA. The within-assay and between-assay coefficients of variation were 4.9–8.9% and 11.1–13.0%, respectively. The mean concentrations of core protein in synovial fluid, serum and urine were 76.4 μg/ml, 104.0 ng/ml and 81.0 ng/ml, respectively. In synovial fluids the concentrations were closely correlated with the concentrations of keratan sulphate as determined by 5D4 (r = 0.94), whereas in serum and urine there was no obvious correlation between the determinations. These findings show that measurement of both core protein and keratan sulphate results in a more precise description of aggrecan turnover.

References (34)

KJ Doege et al.
Complete coding sequence and deduced primary structure of the human cartilage large aggregating proteoglycan, aggrecan
J Biol Chem
(1991)
P Kongtawelert et al.
A new sandwich-ELISA method for the determination of keratan sulphate peptides in biological fluids employing a monoclonal antibody and labelled avidin biotin technique
Clin Chim Acta
(1990)
B Caterson et al.
Identification of a monoclonal antibody that specifically recognizes corneal and skeletal keratan sulphate
J Biol Chem
(1983)
T Saxne et al.
Difference in cartilage proteoglycan level in synovial fluid in early rheumatoid arthritis and reactive arthritis
Lancet
(1985)
EJ-MA Thonar et al.
Serum keratan sulphate — a marker of predisposition to polyarticular osteoarthritis
Clin Biochem
(1992)
MJ Seibel et al.
Antigenic properties of keratan sulphate: influence of antigen structure, monoclonal antibodies and antibody valency
Arch Biochem Biophys
(1992)
JL Funderburgh et al.
Distribution of proteoglycans antigenically related to corneal keratan sulphate proteoglycan
J Biol Chem
(1987)
HJ Møller et al.
Combined alcian blue and silver staining of subnanogram quantities of proteoglycans and glycosaminoglycans in sodium dodecyl sulphate-polyacrylamide gels
Anal Biochem
(1993)
G Stöcker et al.
Characterization of biotin-labeled proteoglycans by electrophoretic separation on minigels and blotting onto nylon membranes prior and after enzymatic digestion
Anal Biochem
(1989)
TE Hardingham et al.
Aggrecan, the chondroitin sulphate/keratan sulphate proteoglycan from cartilage

EJ-MA Thonar et al.

Quantification of keratan sulphate in blood as a marker of cartilage catabolism

Arthritis Rheum

(1985)

D Heinegård et al.

A method for the quantitation of cartilage proteoglycan structures liberated to the synovial fluid during developing degenerative joint disease

Scand J Clin Lab Invest

(1985)

TF Cruz et al.

The effect of maturation and anterior cruciate ligament transection on the level of keratan sulphate in the serum of dogs

J Rheumatol

(1989)

T Saxne et al.

Cartilage proteoglycans in synovial fluid and serum in patients with inflammatory joint disease

Arthritis Rheum

(1987)

DJ Kliner et al.

Keratan sulphate levels in sera of patients bearing cartilage tumors

Cancer

(1987)

A Ratcliffe et al.

Increased concentrations of proteoglycan components in the synovial fluids of patients with acute but not chronic joint disease

Ann Rheum Dis

(1988)

MBE Sweet et al.

Serum keratan sulphate levels in osteoarthritis patients

Arthritis Rheum

(1988)

Cited by (32)

Fluorescence sensing of heparin and heparin-like glycosaminoglycans by stabilizing intramolecular charge transfer state of dansyl acid-labeled AG73 peptides with glutathione-capped gold nanoclusters
2021, Biosensors and Bioelectronics
Sensors that can specifically and accurately detect glycosaminoglycans are rare. Here, a dual-mode platform for fluorescence intensity and lifetime sensing of plasma heparin and fluorescence imaging of heparan sulfate proteoglycan-expressed cancer cells was developed by stabilizing the intramolecular charge transfer (ICT) state of dansyl acid-labeling AG73 (DA-AG73) peptide with glutathione-capped gold nanoclusters (GSH-AuNCs). DA-AG73 peptides, including an electron-donor dimethylamino group and an electron-withdrawing sulfonamide moiety in the labeled DA molecules, emitted weak fluorescence due to the formation of the twisted ICT excited state. The complexation of heparin with DA-AG73 peptides followed by interacting with the GSH-AuNCs could restrict the rotation of the dimethylamino groups of the labeled DA molecules, triggering the transition from their twisted ICT state to ICT excited state. As a result, the fluorescence intensity and lifetime of the labeled DA molecules in DA-AG73 peptides were gradually enhanced with increasing the heparin concentration. The proposed platform provided excellent selectivity toward heparin and heparan sulfate and exhibited two linear calibration curves for quantifying 20–800 nM and 20–1000 nM heparin in the fluorescence intensity and lifetime modes, respectively. The proposed platform was practically applied for the fluorescence intensity and lifetime determination of plasma heparin and for the selective imaging of heparan sulfate proteoglycan-expressed cells.
Clinical presentation and diagnosis of mucopolysaccharidoses
2018, Molecular Genetics and Metabolism
Mucopolysaccharidoses (MPS) are estimated to affect1 in 25,000 live births although specific rates vary between the ethnic origin and country. MPS are a group of lysosomal storage disorders, which cause the buildup of GAG(s) due to insufficient or absent GAG-degrading enzymes. With seven types of MPS disorders and eleven subtypes, the MPS family presents unique challenges for early clinical diagnosis due to the molecular and clinical heterogeneity between groups and patients. Novel methods of early identification, particularly newborn screening through mass spectrometry, can change the flow of diagnosis, allowing enzyme and GAG quantification before the presentation of clinical symptoms improving outcomes. Genetic testing of patients and their families can also be conducted preemptively. This testing enables families to make informed decisions about family planning, leading to prenatal diagnosis.
In this review, we discuss the clinical symptoms of each MPS type as they initially appear in patients, biochemical and molecular diagnostic methods, and the future of newborn screening for this group of disorders.
Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis
2018, Molecular Genetics and Metabolism
To explore the correlation between glycosaminoglycan (GAG) levels and mucopolysaccharidosis (MPS) type, we have evaluated the GAG levels in blood of MPS II, III, IVA, and IVB and urine of MPS IVA, IVB, and VI by tandem mass spectrometry. Dermatan sulfate (DS), heparan sulfate (HS), keratan sulfate (KS; mono-sulfated KS, di-sulfated KS), and the ratio of di-sulfated KS in total KS were measured.
Patients with untreated MPS II had higher levels of DS and HS in blood while untreated MPS III had higher levels of HS in blood than age-matched controls. Untreated MPS IVA had higher levels of KS in blood and urine than age-matched controls. The ratio of blood di-sulfated KS/total KS in untreated MPS IVA was constant and higher than that in controls for children up to 10 years of age. The ratio of urine di-sulfated KS/total KS in untreated MPS IVA was also higher than that in age-matched controls, but the ratio in untreated MPS IVB was lower than controls. ERT reduced blood DS and HS in MPS II, and urine KS in MPS IVA patients, although GAGs levels remained higher than the observed in age-matched controls. ERT did not change blood KS levels in MPS IVA. MPS VI under ERT still had an elevation of urine DS level compared to age-matched controls. There was a positive correlation between blood and urine KS in untreated MPS IVA patients but not in MPS IVA patients treated with ERT. Blood and urine KS levels were secondarily elevated in MPS II and VI, respectively.
Overall, measurement of GAG levels in blood and urine is useful for diagnosis of MPS, while urine KS is not a useful biomarker for monitoring therapeutic efficacy in MPS IVA.
Concentrations of synovial fluid biomarkers and the prediction of knee osteoarthritis 16 years after anterior cruciate ligament injury
2017, Osteoarthritis and Cartilage
Citation Excerpt :
Knee-joint fluid samples were aspirated and centrifuged at 3000 ×g, and aliquots of the supernatants were frozen and stored at −70°C within a few hours of collection. Aggrecan, using monoclonal antibody 1-F215,32; COMP, commercially available assay from AnaMar; MMP-3 and TIMP-1 were quantified by enzyme-linked immunoassays as described5,17,33,34. At baseline, there were no signs of radiological OA in any of the ACL-injured subjects.
To describe the longitudinal patterns of release, and investigate the association between a set of synovial fluid biomarkers at the acute and chronic stage and the development of radiographic knee osteoarthritis (OA) after an anterior cruciate ligament (ACL) injury.
Synovial fluid was aspirated from the acutely ACL-injured knee within the first 2weeks (acute samples), and yearly (chronic samples) up to 7.5 years after injury in 88 subjects (60% men). Non-injured subjects (n = 12) were used as reference group. Aggrecan, cartilage oligomeric matrix protein (COMP), matrix metalloproteinase (MMP)-3 and tissue inhibitor of metalloproteinase (TIMP)-1 in synovial fluid were quantified by immunoassays. The presence of radiographic tibiofemoral (TF) or patellofemoral (PF) OA [Kellgren and Lawrence (K&L) ≥2] was examined with weight-bearing knee radiography 16 years after the ACL injury.
The average acute and chronic SF concentrations of COMP and aggrecan were elevated in comparison with the reference group (P < 0.001). The levels of COMP and aggrecan clearly decreased approximately half a year after the ACL injury, and returned to reference values during the 7.5 years of follow-up. Using logistic regression analysis neither acute nor chronic concentrations of the four biomarkers were associated with the development of radiographic knee OA at the 16 year follow-up.
Increased synovial fluid concentrations of aggrecan and COMP was related to knee injury, but acute and chronic synovial fluid concentrations of aggrecan, COMP, MMP-3 and TIMP-1 failed to predict knee OA 16 years after ACL injury.
Glycosaminoglycans detection methods: Applications of mass spectrometry
2017, Molecular Genetics and Metabolism
Citation Excerpt :
There are different types of ELISA: direct [114], indirect [115], sandwich [116], competitive [117]. ELISA assays developed for GAGs can measure levels of KS [118–120], HS [121–122], C4S [123], C6S [123], DS [123], and hyaluronic acid [124]. ELISA protocols have also been developed to detect GAGs in cells and on cell-surfaces [125–126].
Glycosaminoglycans (GAGs) are long blocks of negatively charged polysaccharides. They are one of the major components of the extracellular matrix and play multiple roles in different tissues and organs. The accumulation of undegraded GAGs causes mucopolysaccharidoses (MPS). GAGs are associated with other pathological conditions such as osteoarthritis, inflammation, diabetes mellitus, spinal cord injury, and cancer. The need for further understanding of GAG functions and mechanisms of action boosted the development of qualitative and quantitative (alcian blue, toluidine blue, paper and thin layer chromatography, gas chromatography, high pressure liquid chromatography, capillary electrophoresis, 1,9-dimethylmethylene blue, enzyme linked-immunosorbent assay, mass spectrometry) techniques.
The availability of quantitative techniques has facilitated translational research on GAGs into the medical field for: 1) diagnosis, monitoring, and screening for MPS; 2) analysis of GAG synthetic and degradation pathways; and 3) determination of physiological and pathological roles of GAGs.
This review provides a history of development of GAG assays and insights about the use of tandem mass spectrometry and its applications for GAG analysis.
An ARGS-aggrecan assay for analysis in blood and synovial fluid
2014, Osteoarthritis and Cartilage
To validate a modified ligand-binding assay for the detection of aggrecanase generated aggrecan fragments with the ARGS neoepitope in synovial fluid (SF) and blood, and to verify the identity of aggrecan fragments found in blood.
An enzyme-linked immunosorbent assay (ELISA) on the Meso Scale Discovery (MSD) platform for detection of ARGS-aggrecan was validated, using a standard made from recombinant human aggrecan. Matched samples of SF, serum, plasma, and urine were obtained from 36 subjects at different time points after knee injury, and analysed for ARGS-aggrecan content. Aggrecan was purified from serum and plasma pools and analysed by Western blot.
The limits of quantification for the ARGS-aggrecan assay was between 0.2 and 0.025 pmol ARGS/ml, and the sensitivity of the assay was improved two-fold compared to when using a standard purified from human donors. The ARGS concentrations were highest in SF (mean, range; 3.02, 0.36–30.22 pmol/ml), 20 times lower in the blood samples (0.14, 0.055–0.28 pmol/ml serum and 0.13, 0.053–0.28 pmol/ml plasma), and 80 times lower in urine (0.036, below detection – 0.087 pmol/ml). Serum-ARGS and plasma-ARGS concentrations were similar, and correlated (r_S = 0.773, P < 0.001). SF concentration correlated with serum concentrations (r_S = 0.420, P = 0.011). In blood, we identified 129–138 kDa aggrecan fragments containing the ARGS neoepitope.
This novel ARGS-aggrecan assay is highly sensitive and suited for analysis of SF and blood samples. Both SF and blood contains ARGS-aggrecan, and ARGS concentrations in SF and serum are correlated.

View all citing articles on Scopus

View full text

ELISA for the core protein of the cartilage large aggregating proteoglycan, aggrecan: Comparison with the concentrations of immunogenic keratan sulphate in synovial fluid, serum and urine

Abstract

J Biol Chem

Clin Chim Acta

J Biol Chem

Lancet

Clin Biochem

Arch Biochem Biophys

J Biol Chem

Anal Biochem

Anal Biochem

Aggrecan, the chondroitin sulphate/keratan sulphate proteoglycan from cartilage

Quantification of keratan sulphate in blood as a marker of cartilage catabolism

Arthritis Rheum

A method for the quantitation of cartilage proteoglycan structures liberated to the synovial fluid during developing degenerative joint disease

Scand J Clin Lab Invest

The effect of maturation and anterior cruciate ligament transection on the level of keratan sulphate in the serum of dogs

J Rheumatol

Cartilage proteoglycans in synovial fluid and serum in patients with inflammatory joint disease

Arthritis Rheum

Keratan sulphate levels in sera of patients bearing cartilage tumors

Cancer

Increased concentrations of proteoglycan components in the synovial fluids of patients with acute but not chronic joint disease

Ann Rheum Dis

Serum keratan sulphate levels in osteoarthritis patients

Arthritis Rheum